Retrospective Study of the Efficacy of Acarbose Combined with Metformin in the Treatment of Type 2 Dia-betes Complicated with Hyperlipidemia
- VernacularTitle:阿卡波糖联合二甲双胍治疗2型糖尿病伴高血脂症疗效的回顾性研究
- Author:
Liju ZHANG
;
Weimin LI
- Keywords:
Type 2 diabetes;
Hyperlipidemia;
Metformin;
Acarbose
- From:
China Pharmacist
2017;20(2):284-286
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy of acarbose combined with metformin in the treatment of type 2 diabetes with hyper-lipidemia. Methods:A retrospective study was adopted. A total of 2000 patients with type 2 diabetes and hyperlipidemia from general practice in the center were enrolled, and among them, 1050 patients were treated with acarbose, and the other 950 ones were treated with acarbose combined with metformin. After 3-month treatment, the therapeutic effect and adverse drug reactions were compared be-tween the groups. The changes of blood glucose and blood lipid were observed before and after the treatment. Results:The total effec-tive rate was 94. 83% in the combined group, which was significantly higher than that in the control group (72. 38%, P<0. 05). Af-ter the treatment, the blood glucose levels of both groups significantly decreased (P<0. 05), and the decrease in the combined group was more significant than that in the control group (P<0. 05). After the treatment, the serum lipid levels of both groups were signifi-cantly improved (P<0. 05), and the improvement in the combined group was much better than that in the control group (P<0. 05). There was no statistically significant difference in the incidence of drug reactions between the groups (P>0. 05). Conclusion:Acar-bose combined with metformin in the treatment of type 2 diabetes with hyperlipidemia can significantly improve blood glucose levels and blood lipid levels, and the clinical efficacy should be affirmed.
